• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Receptor Binding Domain Proteins of SARS-CoV-2 Variants Produced in Nicotiana benthamiana Elicit Neutralizing Antibodies Against Vari

tetano

Editor, Senior Moderator
J Med Virol


. 2022 May 26.
doi: 10.1002/jmv.27881. Online ahead of print.
Receptor Binding Domain Proteins of SARS-CoV-2 Variants Produced in Nicotiana benthamiana Elicit Neutralizing Antibodies Against Variants of Concern


Narach Khorattanakulchai[SUP] 1 2 [/SUP], Suwimon Manopwisedjaroen[SUP] 3 [/SUP], Kaewta Rattanapisit[SUP] 4 [/SUP], Chalisa Panapitakkul[SUP] 1 2 [/SUP], Taratorn Kemthong[SUP] 5 [/SUP], Nutchanat Suttisan[SUP] 5 [/SUP], Kanjana Srisutthisamphan[SUP] 6 [/SUP], Suchinda Malaivijitnond[SUP] 5 [/SUP], Arunee Thitithanyanont[SUP] 3 [/SUP], Anan Jongkaewwattana[SUP] 6 [/SUP], Balamurugan Shanmugaraj[SUP] 4 [/SUP], Waranyoo Phoolcharoen[SUP] 1 2 [/SUP]



Affiliations

Abstract

The constantly emerging severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) with mutations in the receptor-binding domain (RBD) spread rapidly and has become a severe public health problem worldwide. Effective vaccines and optimized booster vaccination strategies are thus highly required. Here, the gene encoding six different RBD (Alpha, Beta, Gamma, Kappa, Delta, and Epsilon variant) along with the Fc fragment of human IgG1 (RBD-Fc) was cloned into plant expression vector and produced in Nicotiana benthamiana by transient expression. Further, the immunogenicity of plant-produced variant RBD-Fc fusion proteins was tested in cynomolgus monkeys. Each group of cynomolgus monkeys were immunized thrice intramuscularly with variant RBD-Fc vaccines at day 0, 21, 42, and neutralizing antibody responses were evaluated against ancestral (Wuhan), Alpha, Beta, Gamma, and Delta variants. The results showed that three doses of the RBD-Fc vaccine significantly enhanced the immune response against all tested SARS-CoV-2 variants. In particular, the vaccines based on Delta and Epsilon mutant RBD elicit broadly neutralizing antibodies against ancestral (Wuhan), Alpha, and Delta SARS-CoV-2 variants whereas Beta and Gamma RBD-Fc vaccines elicit neutralizing antibodies against their respective SARS-CoV-2 strains. The Delta and Epsilon RBD-Fc based vaccines displayed cross-reactive immunogenicity and might be applied as a booster vaccine to induce broadly neutralizing antibodies. These proof-of-concept results will be helpful for the development of plant-derived RBD-Fc-based vaccines against SARS-CoV-2 and its variants. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; immunogenicity; plant-produced recombinant protein; receptor-binding domain; subunit vaccine; variant vaccine.
 
Back
Top Bottom